OTLC Oncotelic Therapeutics, Inc.
Company Updates ·
The result reflects a non-cash increase of approximately $365.4 million in the fair value of the company's GMP Biotechnology investment, partly offset by a tax provision.
Oncotelic's $560,000 note converts at a fixed $0.07 per share and carries 10% interest, and a separate equity purchase agreement with the same lender could add up to $25 million of stock sales.
The company said it was unable to compile the financial information needed for a complete filing. It does not expect a significant change in results from the prior year.
Oncotelic Therapeutics, Inc. describes itself as a clinical-stage biopharmaceutical company developing drugs for orphan oncology indications, including antisense and small molecule injectable drugs for cancer. Its OT-101, an antisense against TGF-beta2, is being advanced through a joint venture, GMP Biotechnology Limited, formed with Dragon Overseas Capital, Limited in March 2022. The joint venture also holds five additional nanoparticle compounds. The company holds an exclusive license to AL-101, an intranasal apomorphine asset for Parkinson's disease, erectile dysfunction and female sexual dysfunction. It is also evaluating CA4P, a vascular disrupting agent, in combination with a checkpoint inhibitor for advanced metastatic melanoma, and OXi4503 for acute myeloid leukemia and myelodysplastic syndromes. Further development of Artemisinin has been put on hold. Its subsidiaries include PointR Data, Inc., which works on artificial intelligence technologies for clinical trials, and Pet2DAO, Inc., which the company plans to use to address the animal health industry.
| Product or program | What it is | Stage |
|---|---|---|
| OT-101 | Antisense against TGF-beta2 for cancers and viruses, advanced through a joint venture | Phase 2 completed in South America for COVID-19 pneumonia |
| AL-101 | Intranasal apomorphine for Parkinson's disease, erectile dysfunction and female sexual dysfunction | |
| CA4P | Vascular disrupting agent with a checkpoint inhibitor for melanoma | Under evaluation; Rare Pediatric Designation granted |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $4,357 | |
| Net income (loss) | $249.3 million | -$4.5 million |
| Cash from operations | -$1.4 million | -$740,277 |
| Cash and equivalents | $86,128 |
Our latest story on this, dated Aug 6, 2025: "Oncotelic Therapeutics issues $560,000 secured convertible note to Mast Hill Fund". The story links the filing or release it is based on. Read the story.
Oncotelic Therapeutics, Inc. trades under the ticker OTLC on OTC.
Oncotelic Therapeutics, Inc. is listed on OTC.
The SEC Central Index Key (CIK) for Oncotelic Therapeutics, Inc. is 908259. Its filings are on SEC EDGAR.
457,512,796 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Oncotelic Therapeutics, Inc. under United States.
Our directory classifies Oncotelic Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Oncotelic Therapeutics, Inc. is US6283411097.
aibio.space lists Oncotelic Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Oncotelic Therapeutics, Inc. describes itself as a clinical-stage biopharmaceutical company developing drugs for orphan oncology indications, including antisense and small molecule injectable drugs for cancer. Its OT-101, an antisense against TGF-beta2, is being advanced through a joint venture, GMP Biotechnology Limited, formed with Dragon Overseas Capital, Limited in March 2022.
OT-101: Antisense against TGF-beta2 for cancers and viruses, advanced through a joint venture Stage: Phase 2 completed in South America for COVID-19 pneumonia.
AL-101: Intranasal apomorphine for Parkinson's disease, erectile dysfunction and female sexual dysfunction Stage: Not stated in text.
Oncotelic Therapeutics, Inc. reported net income of $249.3 million for the fiscal year ended Dec 31, 2025, and used $1.4 million of cash in operations, per its annual report to the SEC.
$4,357 in the fiscal year ended Dec 31, 2025, per its annual report.
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,5.02,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,2.01,3.02,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio